Sibeprenlimab for IgA kidney disease after prior study
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies sibeprenlimab to see if it can improve IgA nephropathy, a kidney inflammation condition. You may be able to join if you finished a previous related Otsuka study without major safety problems and your doctor thinks you could benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You already finished one of two earlier Otsuka studies (and had no safety problems).
- You must be able to sign consent and follow the trial visits and treatment plan.
- If you had a major side effect from the study drug before, you likely cannot join.
- You must not be pregnant, and you must follow birth-control rules if you could become pregnant or if you’re a male who can father a pregnancy.
- You cannot have “nephrotic syndrome” with several specific lab and symptom findings (but isolated high protein alone may be allowed).
- You generally cannot have serious/unstable major medical problems, recent transplant history, or a severe allergic reaction to the drug ingredients.
- You cannot be taking strong immune-suppressing medicines around the start of the trial (except certain short or local steroid uses).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether choosing treatment based on your personal kidney findings can improve outcomes in adults with IgA nephropathy (IgAN). It may help by matching therapy to the type and severity of kidney damage seen on biopsy.
This trial tests a new drug called mezagitamab for adults with IgA nephropathy, a kidney condition. The study aims to see if this drug can help reduce protein in the urine and preserve kidney function. You may be eligible if your kidney function is above a certain level and your urine protein is high enough.
This study tests a drug called sibeprenlimab to see how it affects kidney tissue in people with IgA nephropathy (IgAN), a condition where antibodies build up in the kidneys. It may help protect your kidneys if your disease is still active.
This study tests a new medicine called sibeprenlimab for children and teens with IgA nephropathy, a kidney disease. The medicine may reduce protein in the urine and help protect kidney function.
This trial tests a new gene therapy called PS-002 for adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The treatment aims to reduce kidney damage, and this study will help determine if it is safe and effective.
This trial tests a new medicine called sibeprenlimab to see if it can safely control three types of kidney disease. It may help people whose disease is hard to manage with current treatments.
Hear when a new Immunoglobulin A Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.